Your browser is no longer supported. Please, upgrade your browser.
CARA Cara Therapeutics, Inc. daily Stock Chart
Cara Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.33 Insider Own3.80% Shs Outstand34.15M Perf Week-0.24%
Market Cap424.48M Forward P/E- EPS next Y-1.86 Insider Trans-17.80% Shs Float31.00M Perf Month-5.69%
Income-65.00M PEG- EPS next Q-0.34 Inst Own63.30% Short Float26.67% Perf Quarter-18.12%
Sales0.90M P/S471.65 EPS this Y-109.40% Inst Trans-0.03% Short Ratio8.43 Perf Half Y-25.17%
Book/sh3.39 P/B3.67 EPS next Y-4.50% ROA-85.20% Target Price25.14 Perf Year57.14%
Cash/sh3.29 P/C3.78 EPS next 5Y- ROE-99.60% 52W Range5.85 - 28.50 Perf YTD33.80%
Dividend- P/FCF- EPS past 5Y2.40% ROI- 52W High-56.39% Beta3.11
Dividend %- Quick Ratio16.10 Sales past 5Y- Gross Margin- 52W Low112.48% ATR0.50
Employees34 Current Ratio16.10 Sales Q/Q- Oper. Margin- RSI (14)39.43 Volatility4.52% 3.76%
OptionableYes Debt/Eq0.01 EPS Q/Q39.80% Profit Margin- Rel Volume0.78 Prev Close12.37
ShortableYes LT Debt/Eq0.01 EarningsNov 02 AMC Payout- Avg Volume980.46K Price12.43
Recom1.90 SMA20-6.27% SMA50-7.30% SMA200-19.08% Volume769,076 Change0.49%
Jun-30-17Reiterated Stifel Buy $24 → $20
Jun-30-17Reiterated Laidlaw Buy $35 → $30
Jun-30-17Downgrade Janney Buy → Neutral
Mar-28-17Reiterated Laidlaw Buy $20 → $35
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Mar-10-17Reiterated Laidlaw Buy $17 → $20
Oct-13-16Initiated H.C. Wainwright Buy $20
Aug-08-16Reiterated Needham Buy $27 → $23
Feb-29-16Reiterated Laidlaw Buy $30 → $17
Nov-04-15Initiated Cantor Fitzgerald Buy
Jul-24-15Reiterated Needham Buy $22 → $27
Mar-03-15Initiated MLV & Co Buy $26
Jan-09-15Initiated Canaccord Genuity Buy $20
Dec-09-14Initiated Summer Street Research Buy $20
Feb-27-14Initiated Needham Buy $27
Feb-25-14Initiated Stifel Buy $21
Feb-25-14Initiated Canaccord Genuity Buy $25
Oct-19-17 07:47AM  3 Reasons Cara Therapeutics Is a Better Growth Stock Than Novavax Motley Fool
Oct-17-17 04:01PM  Cara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017 GlobeNewswire
Oct-16-17 04:01PM  Cara Therapeutics to Present Data at Kidney Week 2017 GlobeNewswire
07:00AM  Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus GlobeNewswire
Oct-06-17 06:03AM  Where Will Cara Therapeutics Be in 5 Years? Motley Fool
Oct-04-17 04:01PM  Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference GlobeNewswire
Oct-03-17 08:14AM  CARA Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CARA-US : October 3, 2017 Capital Cube
Sep-12-17 06:48PM  CARA Therapeutics, Inc. Value Analysis (NASDAQ:CARA) : September 12, 2017 Capital Cube
Sep-11-17 10:40AM  CARA Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CARA-US : September 11, 2017 Capital Cube
Sep-10-17 09:37AM  Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc. Motley Fool
Sep-08-17 03:00AM  Stocks With Rising Relative Price Strength: Cara Therapeutics Investor's Business Daily
Sep-07-17 10:30AM  Here's Why Cara Therapeutics Rose 9.6% in August Motley Fool
Sep-06-17 08:39AM  Upcoming Data Releases Fueled Strong Gains in These 2 Marijuana Stocks Last Week Motley Fool
Sep-05-17 08:37AM  Surging Earnings Estimates Signal Good News for Cara Therapeutics (CARA) Zacks
Aug-31-17 09:03AM  Big Investors Are Buying Cara Therapeutics Stock. Should You? Motley Fool +11.43%
08:00AM  Cara Therapeutics to Participate in September Medical Meetings GlobeNewswire
Aug-12-17 11:55PM  Edited Transcript of CARA earnings conference call or presentation 3-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 08:32AM  This Marijuana Stock Skyrocketed Last Week, While 3 Others Plunged Motley Fool
Aug-07-17 08:10AM  Today's Research Reports on Stocks to Watch: Cara Therapeutics, Inc. and Spectrum Pharmaceuticals ACCESSWIRE -8.63%
Aug-06-17 11:42AM  3 Things You Need to Know About Marijuana Stock Cara Therapeutics Motley Fool
Aug-04-17 03:45PM  Why Cara Therapeutics Shares Are Surging 23% Today Motley Fool +22.86%
08:21AM  This Marijuana Stock Could Be 1 Clinical Trial Away From a $1 Billion Valuation Motley Fool
02:35AM  Cara reports 2Q loss Associated Press
Aug-03-17 05:09PM  It's High Time For The Cannabis-Related Drug Pipeline Benzinga
04:01PM  Cara Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
12:30PM  Investor Network: Cara Therapeutics Inc to Host Earnings Call ACCESSWIRE
08:00AM  Cara Therapeutics to Webcast Presentation at the Canaccord Genuity 37th Annual Growth Conference GlobeNewswire
Aug-01-17 07:00AM  Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer GlobeNewswire -6.91%
Jul-30-17 08:21AM  Better Buy: Cara Therapeutics Inc. vs. GW Pharmaceuticals plc Motley Fool
Jul-27-17 04:30PM  Cara Therapeutics to Announce Second Quarter 2017 Financial Results on August 3, 2017 GlobeNewswire
Jul-24-17 02:38PM  ETFs with exposure to CARA Therapeutics, Inc. : July 24, 2017 Capital Cube
Jul-19-17 08:39AM  These 4 Marijuana Stocks All Jumped at Least 10% Last Week Motley Fool
Jul-14-17 01:18PM  ETFs with exposure to CARA Therapeutics, Inc. : July 14, 2017 Capital Cube +10.11%
Jul-13-17 04:10PM  1 Reason Why Cara Therapeutics Ended June Down 11.3% Motley Fool
Jul-12-17 04:56PM  Why This Biotech Could Be Poised For A Run After Toppling 52% In June Investor's Business Daily +7.01%
12:36PM  Here's Why Cara Therapeutics Inc. Is on the Rise Today Motley Fool
12:00PM  This Biotech Popped 7% On Strong Trial Data Investor's Business Daily
08:38AM  UPDATE: Cara Therapeutics shares surge 13.7% premarket on positive trial results MarketWatch
08:04AM  This Marijuana Stock Has Lost More Than Half Its Value in 2 Weeks Motley Fool
08:03AM  3 Stocks to Watch on Wednesday: Square Inc (SQ), Cara Therapeutics Inc (CARA) and Healthcare Services Group, Inc. (HCSG) InvestorPlace
07:00AM  Cara Therapeutics Announces Summary Data From Phase 1 Trial of Oral CR845 in Hemodialysis Patients with Chronic Kidney Disease GlobeNewswire
12:15AM  CORRECTION: Todays Research Reports on Stocks to Watch: Cara Therapeutics and Threshold Pharmaceuticals, Inc. Accesswire
Jul-11-17 03:02PM  Can Cara Therapeutics Stock Bounce Back? Motley Fool
Jul-10-17 04:39PM  Why Best Buy Co Inc (BBY), Abercrombie & Fitch Co. (ANF) and Cara Therapeutics Inc (CARA) Are 3 of Todays Worst Stocks InvestorPlace -10.35%
04:32PM  Here's Why Nobody's Itching to Buy Cara Therapeutics Stock Today Motley Fool
08:10AM  Today's Research Reports on Stocks to Watch: Cara Therapeutics and Threshold Pharmaceuticals Accesswire
Jul-06-17 02:36PM  Cara Therapeutics' New Pain Drug Still Has Value After Failed Clinical Trial Forbes
Jul-05-17 09:26AM  Up in Smoke: Here's Why This Marijuana Stock Absolutely Imploded Last Week Motley Fool -6.88%
Jul-04-17 03:51PM  CARA Therapeutics, Inc. Value Analysis (NASDAQ:CARA) : July 4, 2017 Capital Cube
Jul-03-17 09:33AM  CARA Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CARA-US : July 3, 2017 Capital Cube +6.76%
08:29AM  4 Marijuana Stocks Looking to Combat the Opioid Epidemic Motley Fool
Jun-30-17 05:09PM  Nike and Parkway jump while Cara Therapeutics, Micron drop Associated Press -39.67%
05:04PM  Why Micron Technology, American Outdoor Brands, and Cara Therapeutics Slumped Today Motley Fool
04:41PM  Why Pandora Media Inc (P), Cara Therapeutics Inc (CARA) and Micron Technology, Inc. (MU) Are 3 of Todays Worst Stocks InvestorPlace
04:05PM  Biotech Plunges 40% On Mixed Trial Is There A Silver Lining? Investor's Business Daily
03:01PM  Cara Therapeutics Nose-Dives After Trial Disappoints -- What Now? Motley Fool
12:45PM  Here's Why Cara Therapeutics (CARA) Shares Plummeted 31% Today Zacks
12:17PM  Story Stocks from
12:11PM  2 Biotech Stocks on Analysts Radar: Cara Therapeutics Inc (CARA) and AVEO Pharmaceuticals, Inc. (AVEO) SmarterAnalyst
12:03PM  Why Cara Therapeutics Inc (CARA) Stock Is Plunging Today InvestorPlace
11:41AM  Cara Therapeutics Stock Crashes on Mixed Clinical Results Investopedia
09:11AM  Cara Therapeutics' stock plunges after mixed trial results prompts analyst downgrade MarketWatch
09:00AM  Why Cara Therapeutics Stock Is Crashing Motley Fool
04:39AM  Cara Therapeutics Craters Just After Quick 50% Surge Investor's Business Daily
Jun-29-17 05:29PM  Cara's chronic pain drug data disappoints, shares plunge Reuters -5.34%
04:35PM  Cara reports mixed results from pain drug trial, shares plunge Reuters
04:01PM  Cara Therapeutics Announces Top-line Results From Phase 2b Trial of Oral CR845 in Chronic Pain Patients With Osteoarthritis of the Hip or Knee GlobeNewswire
10:41AM  3 Stocks That Turned $8,000 Into at Least $25,600 in Just One Year Motley Fool
Jun-28-17 04:10PM  Is This Small Biotech Headed For $1 Billion Market Cap Or A Pitfall? Investor's Business Daily
09:21AM  Here's Why These 2 Marijuana Stocks Skyrocketed 32% and 21% Last Week Motley Fool
08:00AM  Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Cara Therapeutics Accesswire
Jun-27-17 04:27PM  These 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing? Motley Fool
02:43PM  Applied Optoelectronics Debuts Atop List Of Hottest Short-Selling Ideas Benzinga
08:38AM  Cara Therapeutics (CARA) Shows Strength: Stock Adds 12.2 % in Session Zacks
07:22AM  Cara Therapeutics Stock Just Hit an All-Time High: Here's Why It Could Go Even Higher Motley Fool
Jun-26-17 04:06PM  Why Cara Therapeutics Shares Are Rallying Again Today Motley Fool +12.19%
11:25AM  Cara Therapeutics Breaks Out to Fresh Highs Investopedia
08:30AM  Biotech Stocks Showing Signs of Resurgence PR Newswire
Jun-23-17 04:40PM  Pot Stock Winners of the Week Investopedia +13.93%
04:19PM  This Small Biotech Is Defying Today's Sectorwide Doldrums Investor's Business Daily
04:14PM  Biotechs Hit Pause On 5-Day Rally As Regeneron, Bluebird Topple Investor's Business Daily
12:20PM  Here's Why Cara Therapeutics Inc. Stock Is Surging Today Motley Fool
10:50AM  Cara Therapeutics Wins Big on FDA Breakthrough 24/7 Wall St.
08:42AM  Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options Zacks
07:00AM  Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients GlobeNewswire
Jun-22-17 09:40AM  Cara Therapeutics Stock Could Break Out on IV CR845 Data Investopedia
08:00AM  Today's Research Reports on Stocks to Watch: Hologic and Cara Therapeutics Accesswire
07:03AM  Forget Cancer Drug Stocks. Here's a Little Biotech That's Easy to Understand Motley Fool
Jun-21-17 04:36PM  Here's Why Emerging Marijuana Stock Cara Therapeutics Inc. Surged as Much as 11% Motley Fool +10.23%
02:53PM  Cara Therapeutics (CARA) Stock Rises After Cr845 Trial Update Zacks
07:00AM  Cara Therapeutics Reports Continuation of Phase 3 Trial of I.V. CR845 in Postoperative Pain Following Interim Assessment GlobeNewswire
Jun-20-17 06:47PM  Cramer's lightning round: Good news from the White House will make this stock a buy CNBC
Jun-12-17 06:47PM  Cramer's lightning round: This DuPont spin-off has moved too much CNBC
Jun-06-17 12:41PM  Harry Boxers two biotech stocks and two tech stocks to watch MarketWatch -5.05%
Jun-05-17 02:06PM  ETFs with exposure to CARA Therapeutics, Inc. : June 5, 2017 Capital Cube
May-31-17 10:36AM  3 Growth Stocks for Bright Investors Motley Fool
May-26-17 10:24AM  Better Know a Marijuana Stock: Cara Therapeutics Motley Fool
08:27AM  CARA Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CARA-US : May 26, 2017 Capital Cube
May-23-17 01:19PM  Harry Boxer: Four stocks locked in a strong uptrend MarketWatch
May-22-17 01:26PM  ETFs with exposure to CARA Therapeutics, Inc. : May 22, 2017 Capital Cube
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The company's lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Menzaghi Frederique Ph.D.VP-Research & DevelopmentAug 04Sale15.003,00045,000117,000Aug 10 05:47 PM
Schoell JosefChief Financial OfficerJul 26Option Exercise2.254,0009,00050,000Jul 28 04:53 PM
CHALMERS DEREK TPresident & CEOJul 14Option Exercise2.4810,00024,8001,107,292Jul 18 06:10 PM
CHALMERS DEREK TPresident & CEOJul 14Sale15.0525,000376,2501,082,292Jul 18 06:10 PM
Menzaghi Frederique Ph.D.VP-Research & DevelopmentJul 14Sale15.003,00045,000120,000Jul 18 06:09 PM
Slagel DeanDirectorJun 29Sale25.87250,0006,468,5641,064,338Jul 03 05:53 PM
RHO Ventures VI LP10% OwnerMar 31Buy18.19500,0009,095,7003,568,057Apr 03 09:19 AM